GUERBET : 2024 full-year results.
2024 full-year results
Very strong business momentum
Full-year revenue: €841.1 million, up 9.0% at constant exchange rates (CER)1 and on a like-for-like basis2
Strong momentum in the Americas (+20.5% at CER and like-for-like), Asia (+10.1%) and EMEA excluding France (+8.8%)
Solid increase in profitability
Restated EBITDA margin3 of 14.9%, versus 13.1% a year earlier
Operating income up 28.2% to €49.6 million
2025 targets
Further growth in profitability: restated EBITDA margin expected above 15%, backed by revenue growth of 3-5% at CER and like-for-like
Free cash flow in positive territory
Villepinte, March 26, 2025, 5:45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing its consolidated financial statements for fiscal year 2024. Full-year revenue came to €841.1 million, up 7.1% compared with 2023. Excluding the currency effect (-€12.3 million), mainly related to the Brazilian real and the Japanese yen, Group sales at constant exchange rates (CER)1 rose by 8.6%. At constant exchange rates and on a like-for-like basis2, Guerbet saw growth of 9.0% in 2024, an acceleration in performance compared with 2023 (+5.9%).
In EMEA, revenue increased by 1.1% at CER and like-for-like. Excluding France, where activity fell (-11.8%) following the reform of the supply chain for contrast agents, growth in EMEA was 8.8%.
In the Americas, sales at CER and like-for-like grew by 20.5%, reflecting an exceptional performance in the first half (+29.1% at CER) linked to the catch-up of lost X-ray sales in 2023, and continued strong momentum in the second half (+13.3%), driven in particular by Latin America.
In Asia, growth reached 10.1% at CER and like-for-like, marking another dynamic year despite the decline in activity in South Korea, affected by a major physician strike.
By business, revenue in Diagnostic Imaging increased by 9.0% at CER and like-for-like, attributable to:
In the X-ray division (+12.6%), volumes and prices remaining very positive, both for Xenetix® and Optiray®.
In the IRM division (+3.0%), momentum in the Dotarem® / EluciremTM franchise slowing as a result of the situation in France: full-year growth of the division was 9.4% excluding the impact of France.
Having reached the unprecedented €100 million mark in fiscal 2024, sales in Interventional Imaging rose by 8.8% at CER and like-for-like, driven all the while by the solid performance of Lipiodol®, particularly in vascular embolization.
In millions of eurosConsolidated financial statements (IFRS)
2023Published
2024Published
Revenue
785.7
841.1
EBITDA*
98.8
119.4
% of revenue
12.6%
14.2%
Operating income/(expense)
38.7
49.6
% of revenue
